<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266655</url>
  </required_header>
  <id_info>
    <org_study_id>BACLAD</org_study_id>
    <nct_id>NCT01266655</nct_id>
  </id_info>
  <brief_title>Baclofen for the Treatment of Alcohol Dependence</brief_title>
  <acronym>BACLAD</acronym>
  <official_title>Baclofen for the Treatment of Alcohol Dependence - BACLAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is first evidence from preclinical and clinical studies for the efficacy of the
      selective GABA-B receptor agonist baclofen in the treatment of alcohol dependence. The aim of
      this trial is to evaluate the efficacy and safety of individually titrated high-dose baclofen
      for relapse prevention in alcohol-dependent patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total abstinence from alcohol and cumulative abstinence duration</measure>
    <time_frame>13-16 weeks (depending on the individually tolerated baclofen dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.</description>
    <arm_group_label>Baclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of alcohol dependence according to ICD-10 (International Classification of
             Mental and Behavioural Disorders, 10th revision) and DSM-IV (Diagnostic and
             Statistical Manual of Mental Disorders, 4th revision) criteria

          -  An alcohol intake of at least two heavy drinking days per week on average (men ≥ 5
             drinks per day; women ≥ 4 drinks per day) and an average overall consumption of 21
             drinks per week or more for men and 14 drinks per week or more for women during the 4
             weeks before detoxification (one standard drink is equal to 12 g absolute alcohol)

          -  Last alcohol consumption within 7-21 days before randomisation

          -  Sufficient German language capabilities

        Exclusion Criteria:

          -  Pregnancy and/or currently breastfeeding

          -  Clinical significant medical conditions or observed abnormalities

          -  Psychiatric illness undergoing treatment with psychoactive drugs

          -  Epilepsy or epileptiform convulsions

          -  Addiction to drugs other than nicotine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Heinz, Prof., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Charité Campus Mitte, Charité - Universitätsmedizin Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Charité Campus Mitte, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Heinz, M.D.</name_title>
    <organization>Department of Psychiatry, Charité Campus Mitte, Charité - Universitätsmedizin Berlin</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

